RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

Background Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC). Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria may underestimate response to ICIs due to the p...

Full description

Bibliographic Details
Main Authors: Christelle de La Fouchardière, Jaafar Bennouna, David Tougeron, Magali Svrcek, Thierry André, Christophe Tournigand, Christophe Borg, Romain Cohen, Marie-Line Garcia-Larnicol, Thibault Mazard, Yves Menu, Dewi Vernerey, Aurélia Meurisse, Benoist Chibaudel
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001499.full

Internet

https://jitc.bmj.com/content/8/2/e001499.full

Similar Items